A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
about
Histamine and Immune Biomarkers in CNS DisordersInternational Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsThe practice of clinical neuropsychology in Australia.Histaminergic system in brain disorders: lessons from the translational approach and future perspectives.Histamine H3 Receptor Antagonists for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials.Enhancing attention in neurodegenerative diseases: current therapies and future directions.Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.Interactions of the histamine and hypocretin systems in CNS disorders.Drugs, games, and devices for enhancing cognition: implications for work and society.Monoaminergic neuropathology in Alzheimer's disease.Old and new acetylcholinesterase inhibitors for Alzheimer's disease.Changes in Histidine Decarboxylase, Histamine N-Methyltransferase and Histamine Receptors in Neuropsychiatric Disorders.Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.Role of the Histamine H3 Receptor in the Central Nervous System.Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects.Hybrid approach to structure modeling of the histamine H3 receptor: Multi-level assessment as a tool for model verificationRemyelinating Pharmacotherapies in Multiple Sclerosis.Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination.The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.Convergent and criterion validity of the CogState computerized brief battery cognitive assessment in women with and without breast cancer.Therapeutics of Neurotransmitters in Alzheimer's Disease.Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers.
P2860
Q26748803-4F026028-EE03-4175-B755-980B4F377A56Q26827568-F6E6BB88-7153-4711-AC18-40AC3F8D8B9FQ30244280-1BA297CE-3EE7-4B75-8E42-DAE1B4CA3929Q34568925-B56B924B-3AB2-49ED-B787-9080138B2D7AQ35786464-BC2D440B-6D73-4B35-AFD1-BBA818BFBDA4Q36274037-6BAFEBD5-5C2D-46D1-BA6A-D9C2536D42C6Q37585464-8F7799C7-98D8-4922-A836-B5D1F395303EQ37639274-DE8E9580-7860-42A1-89F0-6C0D820F1E61Q38534913-6A96E872-F603-4FD0-9D09-DBFD381015A4Q38797653-89EAB90F-4630-4C0A-9132-761DA0BD8D8EQ38809649-AB9D4BFE-431B-4608-9BAB-6BCCB60CB875Q38908823-358F8000-1648-4FEA-8C74-9A85DBA0A326Q38944800-DE7BD68A-C635-4028-900D-29F178AB7436Q38966308-255C64BD-1EFD-4CB7-B7C0-C89BCA1102B6Q38992604-2E5988B1-7F12-492D-AF4D-F7E6862D2DF6Q39738202-480CBB8A-4D94-46D4-91BB-3FE22AF93F22Q42370925-5875363C-C655-483F-85DB-CC2FFB058880Q46682011-27A770DA-4020-498F-9A3C-D738D682FC4BQ47115378-388D2E61-D7F0-4AAE-B6EC-AE172FD64081Q47567135-27AC560E-A4C7-44B8-8BBB-58B879FE2301Q47590961-A01A9610-7F8F-4451-B868-97B2C02616ABQ49672905-A4E63843-1D5D-41F0-8B05-1F29B5A9BBA6Q50044639-2146E895-7A5D-4C9E-8F55-19DA7E87A79CQ53672159-A088A904-005F-4A9C-ACFD-351643BFD732
P2860
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... -moderate Alzheimer's disease.
@en
A randomized, double-blind, pl ...... -moderate Alzheimer's disease.
@nl
type
label
A randomized, double-blind, pl ...... -moderate Alzheimer's disease.
@en
A randomized, double-blind, pl ...... -moderate Alzheimer's disease.
@nl
prefLabel
A randomized, double-blind, pl ...... -moderate Alzheimer's disease.
@en
A randomized, double-blind, pl ...... -moderate Alzheimer's disease.
@nl
P2093
P1476
A randomized, double-blind, pl ...... -moderate Alzheimer's disease.
@en
P2093
Alienor C Berges
Andreas Mahler
Andrew P Nicholls
Conn M Harrington
Isabel Beresford
Joseph P Horrigan
Martin T Lowy
Pradeep J Nathan
Rebecca L Boardley
Richard A Grove
P356
10.2174/1567205010666131212110148
P50
P577
2014-01-01T00:00:00Z